Ann: Receipt of securities in Noxopharm Limited (NOX), page-2

Sydney, 22 January 2018 – Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA) is pleased to announce that, pursuant to the collaboration with Noxopharm Limited (ASX: NOX) to support future development of NOX66, as announced to ASX on 27 December 2017, the Company has now been issued with the following securities by Noxopharm:

• 5,317,123 Fully Paid Ordinary Shares in Noxopharm Limited (ASX: NOX), voluntarily held in escrow until 14 June 2018; and
• 3,000,000 Unlisted Options over NOX stock, expiry 18 January 2020, and exercisable @ $0.80 (NOXAT). These options are unable to be exercised prior to 18 July 2018.

The above securities have an estimated market value of approximately AU$6.5 million on the date of issue.